289 related articles for article (PubMed ID: 25077917)
21. A Pharmacometrics Model to Characterize a New Type of Target-Mediated Drug Disposition (TMDD) - Nonlinear Pharmacokinetics of Small-Molecule PF-07059013 Mediated By Its High-capacity Pharmacological Target Hemoglobin With Positive Cooperative Binding.
Xu M; An G
AAPS J; 2023 Apr; 25(3):41. PubMed ID: 37055588
[TBL] [Abstract][Full Text] [Related]
22. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
[TBL] [Abstract][Full Text] [Related]
23. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
[TBL] [Abstract][Full Text] [Related]
25. An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.
Chadha GS; Morris ME
AAPS J; 2015 Nov; 17(6):1464-74. PubMed ID: 26276217
[TBL] [Abstract][Full Text] [Related]
26. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
27. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
28. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
Gibiansky L; Ng CM; Gibiansky E
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38639818
[TBL] [Abstract][Full Text] [Related]
29. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
Chang HY; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
[TBL] [Abstract][Full Text] [Related]
30. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.
Patidar K; Pillai N; Dhakal S; Avery LB; Mavroudis PD
J Pharmacokinet Pharmacodyn; 2024 Feb; ():. PubMed ID: 38400996
[TBL] [Abstract][Full Text] [Related]
31. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.
Zhao J; Cao Y; Jusko WJ
Pharm Res; 2015 Oct; 32(10):3269-81. PubMed ID: 25939552
[TBL] [Abstract][Full Text] [Related]
32. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
33. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
34. Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.
Elmeliegy M; Lowe P; Krzyzanski W
AAPS J; 2014 Jul; 16(4):810-42. PubMed ID: 24871341
[TBL] [Abstract][Full Text] [Related]
35. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations.
Byun JH; Jeon HS; Yun HY; Kim JK
PLoS Comput Biol; 2024 Apr; 20(4):e1012066. PubMed ID: 38656966
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
[TBL] [Abstract][Full Text] [Related]
37. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
38. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
[TBL] [Abstract][Full Text] [Related]
39. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
Volz AK; Dingemanse J; Krause A; Lehr T
Pharm Res; 2019 Dec; 37(1):2. PubMed ID: 31823033
[TBL] [Abstract][Full Text] [Related]
40. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
